Frost & Sullivan Independent Equity Research

Oramed Pharmaceuticals Inc.: An emerging player in the huge orally delivered therapeutics segment of the global diabetes care market; we initiate our coverage with a price target of NIS 53.2

Oramed Pharmaceuticals (PRNewsFoto/Oramed Pharmaceuticals Inc)

Company: Oramed Pharmaceuticals Inc.        

Sector: Pharmaceuticals

Report type: Initiation of Coverage

Published on: December 23, 2017

Oramed research articles:

Close Menu
Font Resize